AzTrials
AzTrials

Attention-Deficit/Hyperactivity DisorderVEILLETDAHNCT02217371

Role of Circadian and Homeostatic Systems in the Regulation of Wakefulness in Adult Patients With Attention Deficit Disorder With or Without Hyperactivity

A study testing Neuropsychological tests in people with Attention-Deficit/Hyperactivity Disorder, run by University Hospital, Bordeaux at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In a previous protocol, we highlighted an excessive daytime sleepiness at the Maintenance of Wakefulness Tests (MWT) in 36% of adult Attention Deficit Disorder with or without Hyperactivity (ADHD) patients. Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Attention-Deficit/Hyperactivity Disorder
What is being tested?
Neuropsychological tests
Could I receive a placebo?
No, everyone receives an active treatment
How many people
19 participants
Where
1 siteFrance
Study dates
2 Sep 2014to Aug 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • For ADHD patient:
  • Patients male or feminine, from 18 to 50 years old,
  • Patient respondent in the criterion current diagnosis of the ADHD according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV-TR,
  • Meeting the criteria diagnosis of ADHD in the childhood, estimated by the interview " Conners'Adult ADHD Diagnostic Interview for DSM-IV " (CAADID),
  • Patient presenting a total score ≥ 20 at CAARS With at least 6 items of money scales inattention or hyperactivity ≥ 2,
  • Patients deprived of any psychostimulants for 72 hours,
Show all 24Show fewer
  • Presenting at the polygraphy the absence of night-respiratory disorders (AHI < 10 / hour) and of Periodic Limbs Movements (PLMI < 15 / hour), as well as the absence of restless legs syndrome at the interview,
  • Presenting to the MWT an excessive daytime sleepiness: mean latency < 20 min,
  • Absence of syndrome of phase delay according to the criteria of l'ICSD2 (International Classification Sleep Disorders),
  • Having been schooled until class of 3rd,
  • Having regular schedules of life 4 days before going into the study,
  • Beneficiary of a national insurance scheme,
  • Having given in writing their informed consent to participate in the study.
  • For healthy subject:
  • Patients male or feminine, from 18 to 50 years old,
  • Subjects not symptomatic of ADHD (Total score at the Wender Utah Rating Scale strictly lower than 46 on 25 questions concerning the ADHD, and less than four crosses in the more darker cases of first 6 questions of ASRS),
  • Subjects not presenting complaints of sleep, nor excessive daytime sleepiness (No item equal to 4 or 5 at Basic Nordic Sleep Questionnaire (BNSQ), excepted items 16 and 17 and total score at the Epworth Sleepiness Scale < 11),
  • Presenting at the polygraphy the absence of night-respiratory disorders (AHI < 10 / hour) and of Periodic Limbs Movements (PLMI < 15 / hour), as well as the absence of restless legs syndromeat the interview,
  • Not presenting to the MWT an excessive daytime sleepiness: mean latency > 34 min,
  • Absence of syndrome of phase delay according to the criteria of l'ICSD2 (International Classification Sleep Disorders),
  • Having been schooled until class of 3rd,
  • Having regular schedules of life 4 days before going into the study,
  • Beneficiary of a national insurance scheme,
  • Having given in writing their informed consent to participate in the study.

Who cannot join

  • Posted or night work,
  • Any evolutionary affection (Brain tumour, epilepsy, migraine, cerebral vascular accident, calcifies, myoclonia, chorea, neuropathy, muscular dystrophies, dystrophy myotonic…),
  • Psychiatric comorbidity: Current major depressive episode, current hypo obsessive or obsessive episode, schizophrenia,
  • Renal disorders (Renal insufficiency, nephrolithiasis...),
  • Endocrine pathologies (dysthyroidism, diabetes),
  • Drug addiction during the last 6 months,
Show all 14Show fewer
  • Alcohol addiction during the last 6 months,
  • Dependence in the tetra-hydroxy-cannabinol during the last 6 months,
  • Long-term treatment by benzodiazepines,
  • Treatment by atomoxetine,
  • Pregnant and breast-feeding women,
  • People under supervision, guardianship,
  • Person incapable to give personally its consent,
  • Nobody in emergency situation.

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHU de Bordeaux

    Bordeaux, 33000

Other trials in France

About this study

In a previous protocol, we highlighted an excessive daytime sleepiness at the Maintenance of Wakefulness Tests (MWT) in 36% of adult Attention Deficit Disorder with or without Hyperactivity (ADHD) patients. In 40% of cases this sleepiness was associated with a sleep disorder objectified by polysomnography (PSG): apnea hypopnea syndrome (AHI) ≥ 10/h and / or Periodicals Movements of Lower Limb (PLMI) ≥ 15/h. However, among patients with no sleep disorder PSG, we can question the central origin of the Excessive Daytime Sleepiness. Thus, we wish to determine potential changes in the regulation of sleep / wake cycle through a protocol of extended wake.

The principal objective is to compare the objective sleepiness in sleepy patients with ADHD and healthy subjects during a protocol of extended wake.

It's an observational study of interventional type realized in patient with ADHD syndrome deprived of psychostimulant treatment (for 72 hours) and healthy subject, investigating the implication of the homeostatic and circadian systems in the preservation of awakening.

Being tested
Neuropsychological tests
Keywords
ADHD Patient, Healthy subjects, Sleepiness, PSG, MWT, EEG, cognitive tests
Medical subject headings
Attention Deficit Disorder with Hyperactivity, Sleepiness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Neuropsychological testsOther

    The tests are :

    Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT

    These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h).

Study groups in NCT02217371
Study groupRoleWhat they receive
ADHD patientExperimentalNot described
Receives: Other: Neuropsychological tests
Healthy volunteersActive comparatorNot described
Receives: Other: Neuropsychological tests

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparison of objective sleepiness

    Comparison of objective sleepiness in sleepy patients with ADHD and healthy subjects during a protocol of extended wake.

    Measured: at inclusion (day 0)

Secondary outcomes (4)
  1. Theta-alpha band of EEG sleep

    Time constant and asymptotic value of the spectral power of the theta-alpha band of EEG sleep

    Measured: At inclusion (Day 0)

  2. Amplitude and phase of internal temperature

    Measured: At inclusion (day 0)

  3. Score of Karolinska Sleepiness Scale (subjective measure of sleepiness)

    Measured: At inclusion (day 0)

  4. Results of the neuropsychological tests

    • Go/NoGO paradigm
    • Continuous Performance Test and virtual Continuous Performance Test
    • Stroop test and virtual stroop test
    • Wisconsin Card Sorting Test

    Measured: At inclusion (day 0)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Aug 2014 (estimated)
  2. Study start2 Sep 2014
  3. Primary completionMay 2017
  4. Study completionAug 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
19 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02217371
Sponsor's protocol ID
CHUBX 2013/06
Acronym
VEILLETDAH
Status last verified
Aug 2017
First submitted
5 May 2014
Last updated
10 Aug 2017
Results posted
No
Data monitoring committee
No

Publications

  • Bioulac S, Sagaspe P, Tron E, Benard A, Berthomier C, Brandewinder M, Philip P, Taillard J. Does Homeostatic Sleep Pressure Buildup Explain Objective Excessive Daytime Sleepiness in Adults With ADHD? An Exploratory Study. Front Psychiatry. 2021 Feb 19;12:586528. doi: 10.3389/fpsyt.2021.586528. eCollection 2021.

    PubMed 33679469

Questions about this trial

What is this clinical trial studying?

A study testing Neuropsychological tests in people with Attention-Deficit/Hyperactivity Disorder, run by University Hospital, Bordeaux at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 24 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparison of objective sleepiness (time frame: at inclusion (day 0)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02217371, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in